Eli Roza, MD
Nephrology · Hagerstown, MDNPI 1184611444
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $58,490 of the $78,843 with a category attached, or 74.2%. 36 manufacturers reported payments, led by AstraZeneca at 51.7% of the total. Reporting peaked in 2024 at $20,998 and has fallen 93.1% since, to $1,449 in 2025. Among nephrology clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 610 payments — averaging $129.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$41K
- Vifor Pharma, Inc.$12K
- Boehringer Ingelheim$11K
- Lilly USA, LLC$9K
- ANI Pharmaceuticals, Inc.$630
- Otsuka America Pharmaceutical, Inc.$601
- plus $5K from 30 others
What the payments were for
- Consulting fees$3,6005%
- Speaking & faculty fees$58,49074%
- Travel & lodging$4,6416%
- Food & beverage$11,44315%
- Education$6701%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 130 | $40,791 |
| Vifor Pharma, Inc. | 59 | $11,597 |
| Boehringer Ingelheim | 45 | $10,800 |
| Lilly USA, LLC | 50 | $9,090 |
| ANI Pharmaceuticals, Inc. | 17 | $630 |
| Otsuka America Pharmaceutical, Inc. | 25 | $601 |
| Bayer | 34 | $598 |
| OPKO Pharmaceuticals, LLC | 35 | $562 |
| Amgen(2 entities) | 24 | $497 |
| Novo Nordisk | 25 | $484 |
| Mallinckrodt Hospital Products Inc. | 21 | $426 |
| Akebia Therapeutics Inc | 17 | $367 |
| Calliditas Therapeutics US Inc. | 17 | $330 |
| Travere Therapeutics, Inc. | 19 | $291 |
| Fresenius USA Marketing, Inc. | 16 | $275 |
| Mallinckrodt Enterprises LLC | 6 | $186 |
| Aurinia Pharma U.S., Inc. | 9 | $170 |
| Ardelyx, Inc. | 8 | $165 |
| Novartis | 6 | $153 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $145 |
| GSK | 6 | $122 |
| Pfizer | 6 | $120 |
| Ultragenyx Pharmaceutical Inc. | 3 | $71 |
| Biohaven Pharmaceuticals, Inc. | 3 | $59 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $50 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $47 |
| Abbott | 2 | $39 |
| Nxstage Medical, Inc. | 2 | $31 |
| Amarin Pharma, Inc. | 2 | $26 |
| Scpharmaceuticals Inc. | 1 | $25 |
| Johnson & Johnson | 1 | $21 |
| Kyowa Kirin, Inc. | 1 | $20 |
| Genentech USA, Inc. | 1 | $15 |
| Strongbridge US Inc. | 1 | $12 |
| AbbVie | 1 | $12 |
| Biomerieux Inc | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$38,450
- JARDIANCE$18,545
- Veltassa$10,560
- PURIFIED CORTROPHIN GEL$236
How this compares
$78,843 in reported general payments places this provider in the 95th percentile of 285 nephrology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 228 | $326,786 |
| FarxigaDapagliflozin Propanediol | 198 | $175,085 |
| JardianceEmpagliflozin | 116 | $135,485 |
| TrulicityDulaglutide | 66 | $86,480 |
| AuryxiaFerric Citrate | 33 | $69,512 |
| OzempicSemaglutide | 39 | $68,606 |
| RayaldeeCalcifediol | 37 | $61,648 |
| KerendiaFinerenone | 48 | $42,585 |
| RenvelaSevelamer Carbonate | 16 | $30,905 |
| JanuviaSitagliptin Phosphate | 30 | $30,385 |
| EliquisApixaban | 23 | $27,726 |
| RybelsusSemaglutide | 13 | $26,571 |
| VeltassaPatiromer Calcium Sorbitex | 18 | $17,149 |
| Nebivolol Hcl | 165 | $14,377 |
| Paricalcitol | 57 | $5,947 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $9,090 | $413,267294 claims |
| AstraZenecaFarxiga | $40,791 | $175,085198 claims |
| Boehringer IngelheimJardiance | $10,800 | $135,485116 claims |
| Novo NordiskOzempic, Rybelsus | $484 | $95,17752 claims |
| Akebia Therapeutics IncAuryxia | $367 | $69,51233 claims |
| OPKO Pharmaceuticals, LLCRayaldee | $562 | $61,64837 claims |
| BayerKerendia | $598 | $42,58548 claims |
| PfizerEliquis | $120 | $27,72623 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $630 | $1,21415 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 285 nephrology providers in Maryland.
Other nephrology in Hagerstown
- Kiran SamindlaFrederick$491K
- Matthew WeirBaltimore$490K
- Chirag ParikhBaltimore$186K
- Mohamad HanounehBaltimore$174K
- Daniel BrennanBaltimore$133K
- Monika DhillonBaltimore$126K
- Duvuru GeethaBaltimore$91K
- Mohamed AttaBaltimore$65K
- Michelle EstrellaBaltimore$55K
- Zainab ObaidiBaltimore$39K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.